STTK

+ Watchlist + Portfolio

Shattuck Labs, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.66
52-Week Range: $0.79 – $8.33
Market Cap: $727.63M
P/E (TTM): —
EPS (TTM): -0.44
Dividend Yield: —

Advanced Metrics

Price/Book: 5.72
PEG Ratio: —
Return on Equity: -39.21%
Return on Assets: -24.43%
Gross Margin: 0.00%
Operating Margin: -5570.50%
Profit Margin: 0.00%
Current Ratio: 27.59
Debt/Equity: 0.01
Total Debt: $2.67M
Free Cash Flow: $-21.22M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $563.15M

STTK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$652.00K	$1.66M	$5.72M	$1.00M
Research & Development	$82.90M	$74.31M	$67.21M	$35.27M
Selling, General & Admin	$21.08M	$19.30M	$19.08M	$17.23M
Operating Expenses	$103.98M	$93.61M	$86.29M	$52.51M
Operating Income	-$103.33M	-$91.96M	-$80.57M	-$51.51M
EBITDA	-$100.26M	-$87.92M	-$76.74M	-$47.82M
Pretax Income	-$101.94M	-$87.30M	-$75.41M	-$48.81M
Net Income	-$101.94M	-$87.30M	-$75.41M	-$48.81M
Diluted EPS	-2.41	-2.05	-1.49	-0.70
Diluted Shares	42.38M	42.60M	50.76M	69.58M

STTK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$47.38M	$125.63M	$57.39M	$54.19M
Current Assets	$184.58M	$143.22M	$79.22M	$82.47M
Total Assets	$205.32M	$159.56M	$91.05M	$91.03M
Current Liabilities	$24.96M	$11.45M	$8.92M	$7.05M
Total Debt	$4.90M	$4.20M	$3.41M	$2.42M
Total Liabilities	$29.17M	$14.86M	$11.42M	$8.64M
Retained Earnings	-$219.01M	-$306.31M	-$381.72M	-$430.53M
Shareholders' Equity	$176.16M	$144.71M	$79.63M	$82.39M
Working Capital	$159.62M	$131.77M	$70.30M	$75.42M

STTK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$94.50M	-$81.23M	-$60.52M	-$39.88M
Capital Expenditure	-$11.61M	-$407.00K	-$59.00K	-$71.00K
Free Cash Flow	-$106.11M	-$81.64M	-$60.57M	-$39.95M
Depreciation & Amortisation	$3.07M	$4.04M	$3.83M	$3.69M
Stock-Based Compensation	$6.46M	$6.94M	$9.55M	$7.00M
Investing Cash Flow	$49.44M	$110.86M	-$8.51M	-$7.89M
Financing Cash Flow	$171.00K	$48.62M	$787.00K	$44.57M
Share Repurchases	—	—	-$17.00K	—
Net Change in Cash	-$44.89M	$78.25M	-$68.24M	-$3.19M

STTK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$1.00M	$0.00	$0.00
Research & Development	$9.92M	$8.68M	$7.62M	$9.05M	$10.95M
Selling, General & Admin	$4.47M	$4.35M	$4.10M	$4.32M	$4.60M
Operating Expenses	$14.39M	$13.03M	$11.72M	$13.37M	$15.54M
Operating Income	-$14.39M	-$13.03M	-$10.72M	-$13.37M	-$15.54M
EBITDA	-$13.45M	-$12.10M	-$9.80M	-$12.46M	-$14.65M
Pretax Income	-$13.70M	-$12.46M	-$10.06M	-$12.59M	-$14.77M
Net Income	-$13.70M	-$12.46M	-$10.06M	-$12.59M	-$14.77M
Diluted EPS	-0.27	-0.24	-0.14	-0.12	-0.13
Diluted Shares	50.97M	51.00M	72.18M	103.78M	112.23M

STTK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$60.90M	$50.47M	$42.55M	$54.19M	$90.42M
Current Assets	$66.40M	$54.67M	$90.72M	$82.47M	$93.75M
Total Assets	$77.17M	$64.37M	$100.33M	$91.03M	$102.12M
Current Liabilities	$7.32M	$5.34M	$5.34M	$7.05M	$4.25M
Total Debt	$3.19M	$2.97M	$2.63M	$2.42M	$2.89M
Total Liabilities	$9.58M	$7.35M	$7.09M	$8.64M	$6.29M
Retained Earnings	-$395.42M	-$407.88M	-$417.94M	-$430.53M	-$445.30M
Shareholders' Equity	$67.59M	$57.02M	$93.24M	$82.39M	$95.83M
Working Capital	$59.09M	$49.34M	$85.39M	$75.42M	$89.50M

STTK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.03M	-$10.43M	-$8.93M	-$8.49M	-$13.42M
Free Cash Flow	-$12.03M	-$10.43M	-$9.00M	-$8.49M	-$13.42M
Depreciation & Amortisation	$936.00K	$929.00K	$917.00K	$906.00K	$891.00K
Stock-Based Compensation	$1.72M	$1.89M	$1.78M	$1.61M	$2.42M
Investing Cash Flow	$15.60M	$0.00	-$43.49M	$20.00M	$23.85M
Financing Cash Flow	-$57.00K	$0.00	$44.50M	$134.00K	$25.80M
Net Change in Cash	$3.51M	-$10.43M	-$7.92M	$11.64M	$36.23M

Market Snapshot

About

Shattuck Labs is a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine. The company focuses on cancer immunotherapy, designing molecules that simultaneously inhibit checkpoint pathways and stimulate immune responses. Their proprietary Agonist Redirected Checkpoint platform aims to overcome limitations of traditional cancer treatments.